Phaseline

Companies › Nabiqasim Industries (Pvt)

Nabiqasim Industries (Pvt): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Linagliptin
Dipeptidyl peptidase IV inhibitor
DPP4Phase 4Diabetes Mellitus–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06862739LinagliptinPhase 4Diabetes MellitusMetabolic and endocrineApr 2026

Targets

DPP4 (1)

Companies with the same targets

AstraZeneca CSPC Ouyi Pharmaceutical Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair JW Pharmaceutical

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.